Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi & Hao Hu. (2022) Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 555-574.
Read now
Read now
Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Read now
Åsa Ericsson & Adam Fridhammar. (2019) Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. Journal of Medical Economics 22:10, pages 997-1005.
Read now
Read now
Articles from other publishers (16)
Jiejin Zhu, Ying Zhou, Qingyu Li & Gang Wang. (2023) Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review. Advances in Therapy.
Crossref
Crossref
Xinyu Li, Fang Li, Junfeng Wang, Anoukh van Giessen & Talitha L. Feenstra. (2023) Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetologica 60:7, pages 861-879.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Nathorn Chaiyakunapruk, John Attia & Ammarin Thakkinstian. (2022) Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Services Research 22:1.
Crossref
Crossref
Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson & Barrie Chubb. (2022) Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. PharmacoEconomics - Open 6:3, pages 343-354.
Crossref
Crossref
Johannes Pöhlmann, Klas Bergenheim, Juan-Jose Garcia Sanchez, Naveen Rao, Andrew Briggs & Richard F. Pollock. (2022) Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes Therapy 13:4, pages 651-677.
Crossref
Crossref
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson & Pierre Johansen. (2020) Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. PharmacoEconomics 38:9, pages 953-969.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
Pierre Johansen, Jonas Håkan-Bloch, Aiden R. Liu, Peter G. Bech, Sofie Persson & Lawrence A. Leiter. (2019) Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics - Open 3:4, pages 537-550.
Crossref
Crossref
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan & Heleen G. M. van Haalen. (2019) Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics 37:12, pages 1451-1468.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P. Jansen & Adam Fridhammar. (2018) Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLOS ONE 13:2, pages e0191953.
Crossref
Crossref
Alexandre Baptista, Inês Teixeira, Sónia Romano, António Vaz Carneiro & Julian Perelman. (2016) The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. The European Journal of Health Economics 18:8, pages 937-965.
Crossref
Crossref
Åsa Ericsson & Adam Lundqvist. (2017) Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Applied Health Economics and Health Policy 15:2, pages 237-248.
Crossref
Crossref
Maria Giovanna Ferrario, Luis Lizán, Roberta Montagnoli & Antonio Ramírez de Arellano. (2016) Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy. Primary Care Diabetes 10:3, pages 220-226.
Crossref
Crossref
Aliasghar A. Kiadaliri, Ulf G. Gerdtham, Bjorn Eliasson & Katarina Steen Carlsson. (2014) Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Therapy 5:2, pages 591-607.
Crossref
Crossref